Haleon PLC Sponsored ADR ( (HLN) ) just unveiled an update.
On May 1, 2025, Haleon PLC announced the purchase and cancellation of 856,851 ordinary shares as part of its share buyback program initiated on March 28, 2025. This transaction, completed on April 30, 2025, is part of Haleon’s strategic efforts to optimize its capital structure and enhance shareholder value. The buyback reduces the number of shares with voting rights to 9,016,910,492, potentially impacting shareholder notifications under the FCA’s Disclosure Guidance and Transparency Rules.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.
Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes well-known brands in categories such as Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Notable brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
YTD Price Performance: 7.64%
Average Trading Volume: 11,590,398
Technical Sentiment Signal: Sell
Current Market Cap: $45.17B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.